Diabetes drug 'Avandia' to be pulled from shelves

Published: 2010-10-27 07:00:00

Updated: 2010-10-27 07:00:00

U.K.-based GlaxoSmithKline (GSK)’s blockbuster anti-diabetes pill “Avandia” will face being banned in the Korean market as the Korea Food and Drug Administration (KFDA) announced a plan to review the drug once again after much criticism arose regarding its lax monitoring. The meeting will decide ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK